Interleukin-6 (IL-6) is a cytokine that has long been under spotlight in myeloma since late 80s as a driver for myeloma which raised the question of benefit of targeting this cytokine for theurapeutic purposes [53]. This evidence concerns the gene IL6 and plasma cell myeloma.